Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | THPO | P40225 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GMNN | O75496 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331962 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL29757853 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL20341083 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL20340496 | 0.91 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL10050930 | 0.91 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL10070677 | 0.91 | SMN1; SMN2 (0.40) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL10071233 | 0.91 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL15491022 | 0.88 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL20436753 | 0.85 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| SCHEMBL5886643 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800178-A1 | PREPARATION OF ENAMIDE INTERMEDIATE FOR THE SYNTHESIS OF DASOTRALINE | Moehs Ibérica, S.L. (ES) | 2021-04-07 | — | — | EP | claimed |
| EP-3800178-A1 | PREPARATION OF ENAMIDE INTERMEDIATE FOR THE SYNTHESIS OF DASOTRALINE | Moehs Ibérica, S.L. (ES) | 2021-04-07 | — | — | EP | disclosed |
| EP-3800178-A1 | PREPARATION OF ENAMIDE INTERMEDIATE FOR THE SYNTHESIS OF DASOTRALINE | Moehs Ibérica, S.L. (ES) | 2021-04-07 | — | — | EP | disclosed |
| US-10435351-B2 | Enamide process | SUNOVION PHARMACEUTICALS INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180215702-A1 | ENAMIDE PROCESS | SUNOVION PHARMACEUTICALS INC. | 2018-08-02 | — | — | US | disclosed |
| US-10011559-B2 | Preparation of chiral amides and amines | SUNOVION PHARMACEUTICALS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011559-B2 | Preparation of chiral amides and amines | SUNOVION PHARMACEUTICALS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180016224-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016224-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2018-01-18 | — | — | US | disclosed |
| EP-2816024-B1 | Chiral amines | SUNOVION PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| CN-103588659-A | Preparation of chiral amides and amines | SEPRACOR INC | 2014-02-19 | — | — | CN | disclosed |
| US-8524950-B2 | Preparation of chiral amides and amines | SUNOVION PHARMACEUTICALS INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120095106-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095106-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8097760-B2 | Preparation of chiral amides and amines | Sunovion Pharmacuticals Inc. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097760-B2 | Preparation of chiral amides and amines | Sunovion Pharmacuticals Inc. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097760-B2 | Preparation of chiral amides and amines | Sunovion Pharmacuticals Inc. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090149549-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149549-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149549-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011559-B2 | Preparation of chiral amides and amines | PNMT, ALKBH5, ALKBH2 | SLC6A2 374/4885SLC6A4 827/4885SLC6A3 1382/4885 |
| US-20180016224-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH2, ALKBH5 | SLC6A2 363/4885SLC6A4 825/4885SLC6A3 1452/4885 |
| US-20090149549-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH5, ALKBH2 | SLC6A2 374/4885SLC6A4 827/4885SLC6A3 1382/4885 |
| US-20120095106-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH5, ALKBH2 | SLC6A2 374/4885SLC6A4 827/4885SLC6A3 1382/4885 |
| US-20180215702-A1 | ENAMIDE PROCESS | ENO1, ENY2, ALKBH2 | SLC6A2 1680/4885SLC6A4 3378/4885SLC6A3 3049/4885 |
| US-10435351-B2 | Enamide process | ENO1, ENY2, ALKBH2 | SLC6A2 1680/4885SLC6A4 3378/4885SLC6A3 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.